Medical Advocates
Tenofovir Disoproxil Fumarate (Viread)
   
Pediatric Data

New and Noteworthy 
Journal Citations
 Conference Citations
US Treatment Guidelines   


|
 
Tenofovir Main Page Main New/Newsworthy  Home Page      
Last Update:  January 29, 2012
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
January 2012
 
Journal Papers, Abstracts, and Commentaries
       
Safety
 
  A WEEK-IN-REVIEW FEATURED REPORT
 Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically HIV-Infected Children,
Adolescents and Young Adults: A 60-Month Follow-Up Study.
 Viganò A, Bedogni G, Manfredini V, et al
Clin Drug Investig. 2011;31(6):407-15.
 Abstract


Pharmacokinetics

 
  Population Pharmacokinetics of Tenofovir in HIV-1 Infected Pediatric Patients.
Bouazza N, Urien S, Hirt D, et al
J Acquir Immune Defic Syndr. 2011 Aug 18.
 Abstract

Steady-State Pharmacokinetics of Tenofovir Based Regimens in HIV-Infected Pediatric Patients.
King JR, Yogev R, Jean-Philippe P, Graham B,  et al
Antimicrob Agents Chemother. 2011 Jun 13
 Abstract

Efficacy
 
 

A WEEK-IN-REVIEW FEATURED REPORT
A Tailored Dose of Tenofovir Could Reduce Its Impact on Bone Mass in HIV Type 1-Infected
Children and Adolescents: A Report from 5 Years of Clinical Experience.
 Rosso R, Parodi A, Torrisi C, et al
AIDS Res Hum Retroviruses. 2010 Sep 28
 Abstract

Tenofovir Use in Human Immunodeficiency Virus-1-Infected Children in the United Kingdom and Ireland.
 Riordan A, Judd A, Boyd K, et al 
Pediatr Infect Dis J. 2009 Jan 29
 Abstract
 
Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral
Agents as Salvage Therapy: Impact on Bone Mineral Density in HIV-Infected Children.
Gafni RI, Hazra R, Reynolds JC, Maldarelli F, et al 
Pediatrics. 2006 Aug 21;
 Abstract
 
Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents
as Salvage Therapy for Pediatric HIV Infection.
Hazra R, Gafni RI, Maldarelli F, et al
Pediatrics. 2005 Nov 15
 Abstract

Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human
immunodeficiency virus-infected children.
Hazra R, Balis FM, Tullio AN, et al.
 Antimicrob Agents Chemother. 2004 Jan;48(1):124-9.
Abstract
 
Adverse Events
 
 
FULL-TEXT PDF ARTICLE
 Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
 Pontrelli G, Cotugno N, Amodio D,  et al
BMC Infect Dis. 2012 Jan 23;12(1):18. [
 Paper

Prospective study of renal function in HIV-infected pediatric patients receiving
tenofovir-containing HAART regimens.
Soler-Palacín P, Melendo S, Noguera-Julian A, et al 
AIDS. 2010 Nov 11
 Abstract

A Tailored Dose of Tenofovir Could Reduce Its Impact on Bone Mass in HIV Type 1-Infected
Children and Adolescents: A Report from 5 Years of Clinical Experience.
 Rosso R, Parodi A, Torrisi C, et al
AIDS Res Hum Retroviruses. 2010 Sep 28
 Abstract

Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected
children on antiretroviral therapy: a nested case-control study.
Judd A, Boyd KL, Stöhr W, AIDS. 2010 Feb 4.
 Abstract

Decreased bone mineral density with off-label use of tenofovir in children and adolescents
infected with human immunodeficiency virus.
Purdy JB, Gafni RI, Reynolds JC
J Pediatr. 2008 Apr;152(4):582-4.
 Abstract
 
Increased beta-2 Microglobulinuria in HIV-1-Infected Children and Adolescents Treated with
Tenofovir
Papaleo A, Warszawski J, Salomon R, et al 
Pediatr Infect Dis J. 2007 Oct;26(10):949-951.
 Abstract
 
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
Hussain S, Khayat A, Tolaymat A, Rathore MH.  
Pediatr Nephrol. 2006 May 16;
 Abstract

A 12-Month Treatment With Tenofovir Does Not Impair Bone Mineral Accrual in HIV-Infected
Children.
Giacomet V, Mora S, Martelli L, et al
J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):448-450.
 Abstract
Conference Reports, Abstracts, and Posters
       
 
Tenofovir population pharmacokinetics in HIV-infected children and adolescents
J. King,  R. Yogev, A. Wiznia,  et al
(11th Int Wkshop on Clin Pharm of HIV)
 PDF Abstract

POSTER
 Renal Safety of Highly Active Antiretroviral Therapy including Tenofovir in Vertically HIV-Infected
Youths: a 60-Months Longitudinal Study
V Giacomet, G Bedogni, V Manfredin, et al
(17th CROI)
PDF Pester     Abstract

Effect of Tenofovir Disoproxil Fumarate on Risk of Renal Impairment in HIV-1-infected Children on ART:
Nested Case-control Study
A Judd, K Boyd, W Stöhr, et al
(16 CROI)
 Abstract
 
Long-term Effect of HAART Containing Tenofovir on Bone Mass in HIV-infected Children and Adolescents:
A 48-Month Longitudinal Assessment
A Viganò, G Zuccotti, V Giacomet, et al
(16 CROI)
 Abstract
 
Tenofovir toxicity in children: two clinical cases
 Bengleil AS, Kambraki M, Al Fituri, et al 
(Ninth International Congress on Drug Therapy in HIV Infection)
Abstract
 
Impact on bone mineral density of tenofovir-containing HAART in HIV-1 infected children and adolescents:
a report from 5 years of clinical experience
 Rosso R, Di Biagio A, Parodi A, et al
(Ninth International Congress on Drug Therapy in HIV Infection)
Abstract
 
Renal safety of tenofovir in antiretroviral-experienced children: issue related to predicting GFR by
different equations
Martelli L., Giacomet V., Borgonovo S., et al
 (XVI  International AIDS Conference )
 Abstract
 
Experience with tenofovir disoproxil fumarate (TDF) in heavily pretreated HIV-infected children
J T Ramos, M I Gonzalez Tome, P Rojo, et al
(15IAC)
 Abstract
 
POSTER
Pharmacokinetics of Tenofovir DF Oral Suspension in HIV-1-infected Children between
2 and 8 Years of Age
BP Kearney, J Abadi, M Rosenberg. et al 
(11 CROI)
 PDF Poster       Abstract

Safety, Tolerability, and Clinical Responses to Tenofovir DF in Combination with other
Antiretrovirals in Heavily Treatment-experienced HIV-infected Children: Data through 48 Weeks
R Hazra, R Gafni, F Maldarelli, et al
 (11 CROI)
 Abstract
FDA Updates
       
  NEWS RELEASE
FDA Approves New Pediatric Dosing Recommendations for a New 75 mg Prezista Tablet
US FDA
December 18. 2008
News

Tenofovir Main Page Main New/Newsworthy  Home Page      

Tenofovir Main Page